The study investigates the treatment of DLBCL with or without specific genetic alterations.
Aim of the study
The study investigates the treatment of DLBCL with or without specific genetic alterations, response to therapy based on imaging and molecular parameters and causes of the disease.
Who can take part?
Patients suffering from diffuse large B-cell lymphoma (DLBCL) who have not yet been treated.
Procedure
All study participants are examined to determine whether one of the two gene mutations MYD88 L265P and/or CD79A/B is present in the tumor cells.
Study group A: with one or both of these mutations Acalabrutinib,
in combination with the standard therapy R-CHOP.
Study groups B: without these mutations Acalabrutinib,
in combination with the standard therapy R-CHOP.
Study groups C: without these mutations
4 cycles of R-CHOP followed by 2 cycles of Rituximab
Study groups D: without these mutations
Standard therapy R-CHOP
In the study, the medication is administered in so-called cycles; one cycle comprises 21 days.
All study participants receive at least four cycles of combined chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus a
Immunotherapy with rituximab (R-CHOP). This therapy corresponds to the standard treatment of DLBCL.
After completion of the study therapy, check-ups are initially carried out every 3 months, and after 2 years every 6 months. After 5 years, no more checks are carried out as part of the study.
Compensation
Original study name
Therapy adjustment based on PET/CT and circulating tumor DNA in patients with diffuse large B-cell lymphoma
BASEC number
2020-02356
Sponsors